Form 4: Roivant CEO Exercises Options, Sells Shares for Tax

Eric Venker, President and Immunovant CEO of Roivant Sciences Ltd., exercised stock options and subsequently sold a portion of the acquired common shares to cover applicable withholding taxes and exercise costs.

Summary

• Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), reported transactions involving common shares and stock options.
• On December 23, 2025, Venker acquired 313,841 common shares by exercising stock options at $3.85 per share.
• On the same day, he sold 200,000 common shares at a weighted average price of $22.45, with prices ranging from $22.25 to $22.64.
• On December 24, 2025, Venker acquired an additional 117,848 common shares by exercising stock options at $3.85 per share.
• Also on December 24, 2025, he sold 75,000 common shares at a weighted average price of $22.53, with prices ranging from $22.50 to $22.63.
• The sales were described as "exercise and hold" transactions, with shares sold only to cover applicable withholding taxes and the exercise price of the stock options.
• Following these transactions, Venker beneficially owns 1,654,597 direct common shares and 5,444,834 direct stock options.
• The stock options have an exercise price of $3.85 and an expiration date of April 19, 2032.
• These options began vesting on April 20, 2022, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The executive is realizing value from long-held options, which is a positive for personal wealth. The sales are explicitly for tax and exercise cost coverage, mitigating any negative perception of insider selling. The transaction is routine and pre-planned under Rule 10b5-1(c).

Positives

• The exercise of stock options at a significantly lower price ($3.85) compared to the market sale price (around $22.45-$22.53) indicates a substantial gain for the executive.
• The transactions are part of a pre-arranged plan (Rule 10b5-1(c)), suggesting a structured approach to executive compensation and tax management rather than discretionary selling based on new information.

Negatives

• Insider selling, even for tax purposes, can sometimes be perceived negatively by the market, though the stated reason mitigates this.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It primarily reports past insider transactions.

Management Comments

• Represents an exercise and hold transaction, with a sale of Common Shares only to cover applicable withholding taxes and the exercise price of the stock options exercised.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information to analyze broader industry trends or competitive positioning. It reflects an executive's compensation realization within the biotechnology and pharmaceutical sector.

Stakeholder Impact

• Shareholders: The impact is minimal. The sale of shares to cover taxes is a routine event for executives exercising options and does not typically signal a change in company fundamentals or management's long-term outlook. The transactions were pre-planned under Rule 10b5-1(c).

Next Steps

• The remaining stock options will continue to vest in 36 equal monthly installments following the first anniversary of the April 20, 2022 vesting commencement date, subject to continuous service.

Key Dates

Keywords

Roivant Sciences, ROIV, Form 4, insider transaction, stock options, executive compensation, share sale, Eric Venker, Immunovant